The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments

Oncotarget. 2017 Nov 11;8(63):106151-106152. doi: 10.18632/oncotarget.22382. eCollection 2017 Dec 5.

Authors

Maria Reig¹, Álvaro Díaz-González¹, Jordi Bruix¹

Affiliation

¹ Jordi Bruix: Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Spain.

No abstract available

Keywords: hepatocellular carcinoma; new drugs; sorafenib; systemic treatment; trial design.

Publication types

Editorial